This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Bardoxolone methyl

Reata Pharmaceuticals, Inc.

Drug Names(s): RTA 402, CDDO-Me

Description: Bardoxolone is a novel, oral Antioxidant Inflammation Modulator (AIM) that regulates NF-kB and STAT3, transcription factors implicated in both inflammation and cancer.

Bardoxolone potently induces Nrf2, a transcription factor that is a well-validated target for chronic kidney disease (CKD). Nrf2 activates over 250 antioxidant and detoxifications genes within the cell, thereby modulating ROS-mediated endothelial dysfunction and structural remodeling in the kidney.

Bardoxolone has demonstrated significant nephroprotective activity in animal models of kidney injury. In preclinical toxicology studies, reductions in serum creatinine (SC) have been observed across multiple species. These effects on SC are independent of tubular secretion and creatinine production and thus likely reflect an increase in GFR.

Deal Structure: Bardoxolone and a number of related drugs with the same mechanism of action were licensed by Reata from Dartmouth College and The University of Texas M. D. Anderson Cancer Center.

Kyowa Hakko Kirin and Reata
In January 2010, Kyowa Hakko Kirin and Reata Pharmaceuticals announced that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive right to develop and commercialize bardoxolone methyl in Japan, China, Taiwan, Korea and Southeast Asian markets.

Abbott and Reata
In September 2010, Abbott and Reata Pharmaceuticals announced that they had entered into a collaboration agreement to develop and commercialize bardoxolone methyl. Under terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets. Reata will receive upfront and near-term cash payments of $450 million for the licensing rights to bardoxolone and a minority...See full deal structure in Biomedtracker

Partners: Kyowa Hakko Kirin Co., Ltd. AbbVie Inc.

Bardoxolone methyl News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug